NEU.AX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Jun 2024 @ 02:10):

Stats
Today's Volume	531 929
Average Volume	426 449
Market Cap	2.59B
EPS	$0 ( 2024-02-21 )
Next earnings date	( $0 ) 2024-07-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	16.89
ATR14	$0.0240 (0.12%)

Volume Correlation

Long: -0.31 (neutral)

Short: -0.50 (weak negative)

Signal:(50.239) Neutral

Neuren Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Neuren Pharmaceuticals Correlation - Currency/Commodity

0.68
( moderate )

0.59
( weak )

0.00
( neutral )

0.65
( weak )

-0.01
( neutral )

-0.67
( moderate negative )

Neuren Pharmaceuticals Financials

Annual	2023
Revenue:	$231.93M
Gross Profit:	$205.17M (88.47 %)
EPS:	$1.240

FY	2023
Revenue:	$231.93M
Gross Profit:	$205.17M (88.47 %)
EPS:	$1.240

FY	2022
Revenue:	$14.55M
Gross Profit:	$14.54M (99.93 %)
EPS:	$0.00150

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0728

Financial Reports:

No articles found.

Neuren Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.